Third Canadian Province Follows On Biosimilar Switching
New Brunswick Introduces Switching Program, Following British Columbia And Alberta
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
You may also be interested in...
Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.